Given the role of miR-155 in the innate immune response and the fact that it is upregulated in many cancers, our results suggest that manipulating miR-663 levels may help to optimize the use of resveratrol as both an anti-inflammatory and anti-cancer agent against malignancies associated with high levels of miR-155.
Introduction
Epidemiological studies suggest that as many as 25 % of all cancers may be due to chronic inflammation (1) (2) (3) (4) . The connection between inflammation and cancer consists of an extrinsic pathway, driven by inflammatory conditions that increase cancer risk, and an intrinsic pathway, driven by genetic alterations that cause inflammation and neoplasia (2) . Furthermore, inflammatory mediators released by cancer-related inflammation can induce genetic instability, leading to the accumulation of random genetic alterations in cancer cells (3) . Beside resident cell types, such as fibroblasts and adipocytes, tumor microenvironment contains various inflammatory cell types infiltrating the tumor area in response to inflammatory stimuli, such as macrophages, neutrophils and mast cells (5) (6) (7) . Tumor-associated macrophages (TAMs) are thought to play key roles in production of various growth factors, angiogenic factors, proteinases, chemokines and cytokines, through cross-talks with cancer cells and other tumor stromal cells (8) (9) (10) . These factors in turn stimulate cell migration/motility, proliferation, survival, angiogenesis and metastasis, resulting in a dynamic environment that favors the progression of cancer, thus affecting the clinical outcome of malignant tumors (7) . TAMs have thus been described as "obligate partners for tumor-cell migration, invasion and metastasis" (11) . Namely, in a genetic model of breast cancer in macrophage-deficient mice, the tumors developed normally but were unable to form pulmonary metastases in the absence of macrophages (12) . As tumor metastasis is responsible for approximately 90% of all cancer-related deaths, a better understanding of inflammation regulatory mechanisms may potentially allow to optimize the use of anti-cancer drugs that may target TAMs and lower tumor-specific inflammatory response (7) .
MiRNAs (microRNAs) are short non-coding RNAs which regulate the translation and/or degradation of target messenger RNAs (13) , and whose molecular malfunctions are associated with major pathologies such as cancers (14) or autoimmune diseases (15) (27,31,32). In adipocytes, resveratrol inhibits the production of the TNF-induced MCP-1, which has been implicated in chronic low grade inflammation, a key feature of obesity type 2 diabetes (33).
To date, it is not known if the anti-tumor and anti-inflammatory effects of resveratrol may rely on the modulation of expression of either pro-inflammatory or anti-inflammatory miRNAs. To address this question, we pretreated human THP-1 monocytes with resveratrol before challenging them with LPS. We show that resveratrol impairs the upregulation of oncogenic pro-inflammatory miR-155 by LPS, at least in part through the upregulation of miR-663, a miRNA targeting JunB and JunD transcripts.
Materials and methods

Microarray analyses
RNAs extracted with TRIzol (Invitrogen) were subsequently subjected to DNase digestion (Turbo-DNase-Ambion). Affymetrix and miRNA microarray analyses were done at the Ohio State University microarray facility.
Cell culture, treatment and transfection
THP-1 cells were electroporated using the AMAXA kit (Lonza). LPS stimulation was done with Salmonella enteritidis-derived LPS (100 ng/ml, Sigma). Whenever needed, cells were pretreated 14 hours with either the vehicle (ethanol) or resveratrol 50 M.
Isolation and treatment of human blood monocytes
Human peripheral blood monocytes were obtained from healthy donors. Monocytes were enriched using a Monocyte Isolation Kit with utoMACS Separator according to the manufacturer's instructions (Miltenyi Biotec). They were subsequently grown for 24 hours in RPMI 1640 medium with glutamax-I (Lonza) supplemented with 10% fetal bovine serum (Lonza) in standard 6 conditions, and exposed to 100 ng/mL CSF-1. Cell viability was assessed using Trypan blue.
Monocytes were then treated for 14 hours with either the vehicle or resveratrol 30 M before RNA extraction.
RNase-protection assays
Assays were performed using the mirVana miRNA Probe Construction Kit and the mirVana miRNA Detection Kit from Ambion. RNAs were incubated overnight at 46 °C in the presence of 8 x 10 4 cpm of antisense RNA probe and then digested for 40 minutes at 37 °C using a 1/50 dilution of the provided RNAse A/RNase T1 solution. 
Preparation of clones and mutagenesis
Western blots
Anti-JunB, anti--Tubulin and anti-GAPDH antibodies were from Cell Signaling
Technology. Anti-JunD was from Abcam. Anti-cMaf was from Santa Cruz. The relative intensities of the bands of interest, prealably normalized to GAPDH or Tubulin, are given under each panel in percent of the respective control sample.
Results
Resveratrol upregulates miR-663
Affymetrix micro-arrays showed that resveratrol modulated the levels of a number of transcripts in THP-1 cells, expectedly upregulating those coding for anti-proliferation factors while downregulating those coding for pro-proliferation factors (MIAME E-TABM-782). The most significant change was a roughly 20 times upregulation of LOC284801 transcripts, which contain the sequence of pre-miR-663 and thus represent miR-663 primary transcripts. In silico analysis using TargetScan (http://www.targetscan.org/) showed that miR-663 potentially targets transcripts of several genes implicated in the immune response (Supplementary Table I) , and especially JunB, JunD and FosB, which encode AP-1 factors known to activate many cytokine genes in partnership with NFAT factors (34).
Due to miR-663 base composition (20 CG/22 nt), no TaqMan probe is presently available for qRT-PCR. However, miRNA micro-arrays also showed that resveratrol upregulates miR-663 by 8 roughly 75 % (MIAME E-TABM-780). This was further confirmed by RNase-protection assays ( Figure 1 ). Furthermore, miRNA micro-arrays (to be submitted upon acceptation of the manuscript) also showed that a lower dose (30 M) of resveratrol still induced similar changes in miRNA populations from human blood monocytes, with the levels of miR-663 increasing roughly by 30 %.
MiR-663 targets AP-1 activity as well as JunB and JunD transcripts
In the presence of LPS, both the surge of AP-1 activity and the upregulation of JunB, an AP-1 factor whose transcript levels peak within the first hour of LPS challenge (35) Figure 4C ). In addition, 663-I slightly but significantly limited the capability of resveratrol to downregulate miR-155 ( Figure 4D ). Thus, some of the effects of resveratrol on oncogenic pro-inflammatory miR-155, and therefore also presumably some of its anti-tumor effects, are due to its upregulation of miR-663.
Discussion
Our study provides the very first data concerning the effects of resveratrol on miRNAs and miR-663 independent effects were also taking place. This was probably due to the fact that resveratrol downregulates the pro-inflammatory NF-B activity (32), which is needed for JunB activation (40) . Also, 663-I failed to increase JunB levels following LPS challenge. This is probably due in part to the fact that LPS challenge decreased miR-663 levels. It is also possible that Significantly different from Pre-miR-Control, *, P < 0.001, **, P < 0.0001. Values represent the mean ± standard deviation (n = 3). * and **, significantly different from the corresponding mockchallenged sample, *P < 0.014 and **P < 0.004. o and oo, significantly different from LPS-challenged vehicletreated Control, oP < 0.02 and ooP < 0.0001. #, significantly different from LPS-challenged resveratrol-treated Control, P < 0.05.
